Exec Chat: Steven Mickelsen Helps Acutus Translate Science Into Improved Outcomes
Mickelsen, an electrophysiologist at the University of Iowa, recently joined the rapidly growing San Diego-area company as Chief Translational Science Officer and is helping to guide the company’s development of novel electrophysiology therapies to treat cardiac arrhythmias.
You may also be interested in...
The IPO is expected to raise $166m to support R&D of new arrhythmia mapping and ablation technologies and expand commercial operations.
New trial results show Acutus Medical's AcQMap platform has the ability to classify conduction patterns and localized non-pulmonary-vein therapeutic targets for ablation to treat atrial fibrillation, which could have implications for both treatment of atrial fibrillation and understanding the genetic markers for this common arrhythmia, according to the authors.
The company’s revenue was down just 1% year-over-year in the third quarter of fiscal 2021, despite the ongoing impact of the pandemic.